Finoriq research workspace
Atara Biotherapeutics, Inc. (ATRA) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Atara Biotherapeutics, Inc. (ATRA).
Company Snapshot
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
- Company
- Atara Biotherapeutics, Inc. (ATRA)
- Ticker
- ATRA
- Market Cap
- $75.6M
- Latest Price
- $8.39
- Industry
- Biotech & Pharma
Atara Biotherapeutics, Inc. (ATRA) Recent Insider Transactions
Recent market insider transaction records indexed for Atara Biotherapeutics, Inc. (ATRA).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Grant-Huerta YaninaChief Accounting Officer | S | Disposed | -$122 | 2026-03-02 |
| Grant-Huerta YaninaChief Accounting Officer | S | Disposed | -$8,145 | 2026-03-02 |
| Grant-Huerta YaninaChief Accounting Officer | S | Disposed | -$1,916 | 2026-03-02 |
| Grant-Huerta YaninaChief Accounting Officer | S | Disposed | -$508 | 2026-03-02 |
| Nguyen AnhCoPresident and CEO | S | Disposed | -$1,006 | 2026-03-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.